Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 4, 2007, Pages 1319-1325

  Kaplan, Robert C ^a   McGinn, Aileen P ^a   Pollak, Michael N ^b   Kuller, Lewis H ^c   Strickler, Howard D ^a   Rohan, Tom E ^a   Cappola, Anne R ^d   Xue, XiaoNan ^a   Psaty, Bruce M ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34147183436     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1631     Document Type: Article

References (39)

1. Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha Jr PM 1999 Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care 22:585-592
2. Le Roith D 1997 Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 336:633-640
3. Friehs I, Stamm C, Cao-Danh H, McGowan FX, del Nido PJ 2001 Insulin-like growth factor-1 improves postischemic recovery in hypertrophied hearts. Ann Thorac Surg 72:1650-1656
4. Li B, Setoguchi M, Wang X, Andreoli AM, Leri A, Malhotra A, Kajstura J, Anversa P 1999 Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res 84:1007-1019
5. Anwar A 2002 Tumor necrosis factor-A regulates insulin-like growth factor-1 and insulin-like growth factor binding protein-3 expression in vascular smooth muscle. Circulation 105:1220-1225
6. Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA 2004 Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci USA 101:9855-9860 0
7. Donahue LR, Hunter SJ, Sherblom AP, Rosen C 1990 Age-related changes in serum insulin-like growth factor-binding proteins in women. J Clin Endocrinol Metab 71:575-579
8. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL 2005 Insulinlike growth factors and coronary heart disease. Cardiol Rev 13:35-39
9. Rosen T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288
10. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN 1999 Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84:453-457
11. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T 2002 Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case- control study. Circulation 106:939-944
12. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D 2004 The prospective association of serum insulin-like growth factor I (IGF-I) and IGFbinding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 89:114-120
13. Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K, Jorgensen JO 2005 Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 90: 5937-5941
14. Schuler-Luttmann S, Monnig G, Enbergs A, Schulte H, Breithardt G, Assmann G, Kerber S, von Eckardstein A 2000 Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler Thromb Vasc Biol 20:E10-E15
15. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE 2003 Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 157:25-31
16. Kawachi S, Takeda N, Sasaki A, Kokubo Y, Takami K, Sarui H, Hayashi M, Yamakita N, Yasuda K 2005 Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler Thromb Vasc Biol 25:617-621
17. Watanabe T, Itokawa M, Nakagawa Y, Iguchi T, Katagiri T 2003 Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens 16:754-760
18. Sandhu MS, Heald AH, Gibson JM, Cruickshank JM, Dunger DB, Wareham NJ 2002 Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359: 1740-1745
19. Perls TT, Reisman NR, Olshansky SJ 2005 Provision or distribution of growth hormone for 'antiaging': clinical and legal issues. JAMA 294:2086-2090
20. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary D, Psaty BM, Rautaharju P, Tracy RP, Weiler PG 1991 The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1:263-276
21. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D 1999 Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19:538-545
22. O'Leary, DH, Polak JF, Kronmal RA, Savage PJ, Borhani NO, Kittner SJ, Tracy R, Gardin JM, Price TR, Furberg CD 1996 Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke 27:224-231
23. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S 1995 Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 5:278-285
24. SHEP Cooperative Research Group 1991 Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265:3255-3264
25. Longstreth Jr WT, Bernick C, Fitzpatrick A, Cushman M, Knepper L, Lima J, Furberg CD 2001 Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology 56:368-375
26. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E 2002 Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:1099-1106
27. Therneau TM, Li H 1999 Computing the Cox model for case cohort designs. Lifetime Data Anal 5:99-112
28. Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, Bovill E, Gottdiener JS 1999 Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. Arch Intern Med 159:1339-1347
29. Lumley T, Kronmal RA, Cushman M, Manolio TA, Goldstein S 2002 A stroke prediction score in the elderly: validation and Web-based application. J Clin Epidemiol 55:129-136
30. Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O'Leary D, Psaty B, Robbins J 1994 Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol 139:1164-1179
31. Frustaci A, Gentiloni N, Russo MA 1996 Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 335:672- 673; discussion 673-674
32. Tanriverdi F, Eryol NK, Atmaca H, Unluhizarci K, Ozdogru I, Sarikaya I, Bayram F, Kelestimur F 2005 The effects of 12 months of growth hormone replacement therapy on cardiac autonomic tone in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 62:706-712
33. McCusker RH, Clemmons DR 1997 Use of lanthanum to accurately quantify insulin-like growth factor binding to proteins on cell surfaces. J Cell Biochem 66:256-267
34. Chan SS, Twigg SM, Firth SM, Baxter RC 2005 Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. J Clin Endocrinol Metab 90:6588-6595
35. Franklin SL, Ferry Jr RJ, Cohen P 2003 Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 88:900-907
36. Rajah R, Lee KW, Cohen P 2002 Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-α-induced apoptosis: role of Bcl-2 phosphorylation. Cell Growth Differ 13:163-171
37. Janssen JA, Jacobs ML, Derkx FH, Weber RF, van der Lely AJ, Lamberts SW 1997 Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:2809-2815
38. Frystyk J, Hojlund K, Rasmussen KN, Jorgensen SP, Wildner-Christensen M, Orskov H 2002 Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J Clin Endocrinol Metab 87:260-266
39. Chen JW Ledet T, Orskov H, Jessen N, Lund S, Whittaker J, De Meyts P, Larsen MB, Christiansen JS, Frystyk J 2003 A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 284:E1149-E1155